Tag: biosimilars
Adverse Event Monitoring for Biosimilars: How Safety Surveillance Works Today
Biosimilars offer cost savings but require advanced safety monitoring due to their complex biology. Learn how adverse event tracking works globally, where systems succeed or fail, and what patients and providers can do to ensure safety.
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic patent protection in the U.S. delays biosimilar entry for 12 years after FDA approval, blocking competition and keeping drug prices high. Learn how the BPCIA, patent thickets, and high development costs create a system that benefits manufacturers - not patients.
